Antitumor activity of N-acetyl-D-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acetylglucosamine chemistry MeSH
- Adjuvants, Immunologic therapeutic use MeSH
- Glycoconjugates chemistry therapeutic use MeSH
- Hemocyanins therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Melanoma drug therapy pathology MeSH
- Disease Models, Animal MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Skin Neoplasms drug therapy pathology MeSH
- Antineoplastic Agents therapeutic use MeSH
- Drug Synergism MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetylglucosamine MeSH
- Adjuvants, Immunologic MeSH
- Glycoconjugates MeSH
- Hemocyanins MeSH
- keyhole-limpet hemocyanin MeSH Browser
- Antineoplastic Agents MeSH
N-Acetyl-D-glucosamine-substituted glycoconjugates (GCJs) with the polyamidoamine (GN8P) or calix[4]arene (GN4C) scaffold represent ligands for NKR-P1 molecule and induce NK cell-mediated cytotoxicity in vitro. The in vivo effect of these GCJs on mouse melanoma model was determined when administered either alone or in combination with non-specific immunostimulator keyhole limpet hemocyanin (KLH). All types of treatment significantly reduced the tumor growth on day 23, while GN4C as well as KLH were effective continuously (from day 14). The GN4C also induced the longest mean survival time (46.3 ± 11.1 d), followed by KLH+GN4C (36.4 ± 12.1), KLH (35.6 ± 6.5), KLH+GN8P (35.6 ± 6.7), and GN8P (32.4 ± 7.0), compared to controls (29.8 ± 3.6). The B16F10 specific cytotoxicity of peripheral blood cells was significantly elevated by both KLH and GN8P, whereas not by GN4C. KLH increased the effect of the GN4C, but did not influence that of GN8P. GN4C was proved to exert anticancer activity in mouse melanoma model. The combination of KLH with GCJs did not generate synergism.
See more in PubMed
J Neuroimmunol. 2002 Sep;130(1-2):55-65 PubMed
Int Immunopharmacol. 2009 Jun;9(6):792-9 PubMed
Eur Urol. 2000;37 Suppl 3:45-9 PubMed
Carbohydr Res. 2007 Sep 3;342(12-13):1781-92 PubMed
Annu Rev Immunol. 2005;23:225-74 PubMed
Nature. 1994 Nov 10;372(6502):150-7 PubMed
Am J Surg. 2003 Nov;186(5):552-5 PubMed
Int Immunol. 2010 Mar;22(3):167-77 PubMed
Bioorg Med Chem. 2010 Feb 15;18(4):1434-40 PubMed
J Surg Res. 2002 Dec;108(2):279-84 PubMed
J Biotechnol. 2002 May;90(3-4):269-90 PubMed
Folia Microbiol (Praha). 2009;54(4):364-8 PubMed
Am J Surg. 2007 Nov;194(5):628-32 PubMed
Micron. 1999 Dec;30(6):597-623 PubMed
Int J Oncol. 2003 Aug;23(2):285-96 PubMed
Adv Exp Med Biol. 2001;495:343-7 PubMed
Am J Surg. 2007 Feb;193(2):284-7 PubMed
Nkrp1 family, from lectins to protein interacting molecules
